Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. - Wikidata - awgldk - TriplyDB

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.

http://www.wikidata.org/entity/Q33805259

about

Risk of Injurious Fall and Hip Fracture up to 26 y before the Diagnosis of Parkinson Disease: Nested Case-Control Studies in a Nationwide Cohort Changing perceptions in osteoporosis.Persistent mucosal damage and risk of fracture in celiac disease.The role of SERMs in the management of postmenopausal osteoporosis.Bone densitometry is not a good predictor of hip fracture.External review and validation of the Swedish national inpatient register.Raloxifene: a review of its use in postmenopausal osteoporosis.Risks and benefits of hormone replacement therapy.Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents.A case-control study on the effect of hormone replacement therapy on ischaemic heart disease.Hormones after menopause?Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.Low-dose hormone replacement therapy: effects on bone.Length of hospital stay after hip fracture and short term risk of death after discharge: a total cohort study in Sweden.Recent concerns surrounding HRT.Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.Classic yin and yang tonic formula for osteopenia: study protocol for a randomized controlled trial.Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease.Clinical appraisal of the Women's Health Initiative.Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study.Polymorphisms in the CYP19 gene that influence bone mineral density.Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.Genistein promotion of osteogenic differentiation through BMP2/SMAD5/RUNX2 signaling.Preparative Purification of Bioactive Compounds from Flos Chrysanthemi Indici and Evaluation of Its Antiosteoporosis Effect Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores.Clec11a/osteolectin is an osteogenic growth factor that promotes the maintenance of the adult skeleton.Risk of hip fracture in Addison's disease: a population-based cohort study.Mediterranean Diet and Hip Fracture in Swedish Men and Women.Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding.Cardiovascular diseases and future risk of hip fracture in women.Coeliac disease and the risk of fractures - a general population-based cohort study.Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals.Risk factors for hip fracture and a possible effect modification by hormone replacement therapy. The Danish nurse cohort study.Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway.Lifestyle factors and choice of hormone replacement therapy among Danish nurses.Birth weight is not associated with risk of fracture: results from two Swedish cohort studies.Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007).Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.Therapeutic potential of oestrogen receptor ligands in development for osteoporosis.Endogenous hormones, muscle strength, and risk of fall-related fractures in older women.

P2860

Q28601487-A41FE1D2-D0F0-4B9A-AF60-C41AFD39DDC1 Q33545020-27F7E543-2BF9-4517-B00E-A6F16807BADF Q33570033-E64BBE0E-1FE1-47FC-8152-F689901F8DA3 Q33757760-67B407AE-4B9F-4FAE-B475-165618D22CA8 Q33807397-9D260113-5D54-45FD-9B57-84C1E51B2B19 Q33928068-F89DFA1B-24C3-41BF-99EC-BD7EB33E8B45 Q34030136-89E0EE90-94D4-42C6-BE06-8C0FE9A0D099 Q34039811-90B32F7C-301E-4587-9220-7E5A071249EF Q34087262-312B1435-CB63-4129-89A4-204182DC098D Q34223276-A86FF102-FC13-432A-8827-295C92C598AF Q34267973-79E5C068-EC6B-4EC3-817B-2B740C451466 Q34617383-E7CA0EBC-2A59-4D21-A790-DAEE6CC61DF8 Q34672074-71FCDB4C-320B-46F4-A4B5-9E25AFF503C2 Q35158178-BC2925A6-ED1A-429A-89CD-C433BD9DF494 Q35178631-E4E1BA6F-4500-4992-85CD-771CC60CAF69 Q35194552-E43EE9D1-E9AA-4478-98E7-DBE1651B678B Q35206132-1DABC928-985D-4CC6-B230-1545FF0DCE50 Q35918730-2E24FD32-4EAB-4BBB-9F26-24AB54EA8E8E Q36072505-36487828-23EE-4B89-A360-C0FFF50B80CE Q36535984-711D0542-90BF-4779-A645-2526FB6C8341 Q36772834-4FCA5A5A-A5B5-4DE9-8889-C542DEB00CB5 Q36782950-7FD39592-9C01-4A36-B671-34C156876E57 Q37381678-C86ECFEA-8B70-4872-AD89-BF32128F8F83 Q37418832-38E8E321-0EF5-4069-B52A-81C6B3F430D1 Q37427052-56CC858A-E85E-4E28-A2D3-C7624B073968 Q37506244-F9FD2237-0ECC-4FDF-A419-570F88C13291 Q38440800-02D725E5-3E2E-4785-A4C4-5B28BE6413DA Q38848411-CF1A4112-5126-4DB5-8CF4-A925ACCAACD2 Q39408981-1829A9F4-06D8-47A8-AED2-9EDDD43A1190 Q40214496-18E18464-CB9F-4D39-9E75-878211F66AEA Q40246398-0566BAEC-01FC-406C-8C7B-EEB11318BBF5 Q42757321-BAAEE480-CFF6-4188-AE36-2B300A26A1D4 Q43642044-E25922BA-4CCD-4377-B025-325A9CA61E10 Q43728726-B9E56302-4428-4062-BB81-46CC4FE06F71 Q43944129-C0B5C1AC-3826-4F35-9962-8F6ED39CB496 Q44068948-A13FDE25-2CFD-4440-A924-060CAB08E8EE Q44097503-F945B1A6-5AD9-440F-BCA8-1C09BF981E6A Q45196993-6352562A-FB52-4C53-A924-2599B6E83736 Q46576596-292636CC-5E36-4E54-8F8A-8D3D570B1858 Q46925977-7A9A4E66-DD18-488F-97FB-3A7B5784B82F

P2860

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.

http://www.wikidata.org/entity/Q33805259

description

1998 nî lūn-bûn

@nan

1998 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Hormone replacement therapy an ...... dish Hip Fracture Study Group.

@ast

Hormone replacement therapy an ...... dish Hip Fracture Study Group.

@en

type

label

Hormone replacement therapy an ...... dish Hip Fracture Study Group.

@ast

Hormone replacement therapy an ...... dish Hip Fracture Study Group.

@en

prefLabel

Hormone replacement therapy an ...... dish Hip Fracture Study Group.

@ast

Hormone replacement therapy an ...... dish Hip Fracture Study Group.

@en

P1433

Q33805259-49D64B04-75FA-4753-951F-6FB9E753E32B

P1476

Q33805259-4438CBE0-FD1A-4EDC-9129-F4C8212A60D5

P2093

Q33805259-528B938E-FDEB-4CD3-B753-1C0DED2E7CFB

Q33805259-874AAC31-246E-42F0-8C08-DD2B567F3AD9

Q33805259-9975F380-D5E7-4CA4-883C-2ACEAB987A72

Q33805259-AF6886FE-016D-4A1A-9FFC-AD82209A2203

Q33805259-CB0DE217-F42C-4601-893F-8B9AC7C75BAD

Q33805259-D1E309AB-63A6-4993-B55E-6198A3F5FC39

P2860

Q33805259-0FC29791-B57A-4631-A499-DD8D87E54479

Q33805259-1BA7DC78-BCAF-4435-9EB1-D818BB298DA7

Q33805259-20C2DA12-5679-45BD-9E65-467378A0DD70

Q33805259-2B9C18CA-59F2-4758-8475-6EAC7BB7C8C1

Q33805259-3F8D8742-1DDA-4AA9-BF16-E5AB85DC8681

Q33805259-4F323B60-AD35-4715-8C6A-09D323F47E57

Q33805259-5AC81FFB-FF93-45A9-9E1E-EC6B19B4E1F1

Q33805259-65E55B80-E647-4C84-8576-607094A55E8E

Q33805259-73DA461F-59B5-4008-A5BF-F10580F7D4D8

Q33805259-75A5AF62-6E95-4CB4-9463-C852FD25D608

P304

Q33805259-8B35118E-BCD7-4BA6-8D5E-3F65A7D763A8

P31

Q33805259-AF4303AC-1DC1-4064-9D29-01C5038FC950

P356

Q33805259-9155CE55-25E2-4CC0-95A8-2852F58D3B70

P407

Q33805259-CEA30641-07EF-4179-94F7-85028C4ECE5E

P433

Q33805259-92243847-E3AB-4691-9665-A3C3EF0DDE0E

P478

Q33805259-496ECD0C-C09F-48C7-A7E7-076315B74705

P50

Q33805259-1411A74C-5C77-4BD2-B05F-07C29E36411F

Q33805259-657D50CC-A60D-4F04-8873-F3AF6CCBDB97

P577

Q33805259-51C53D3C-BFDC-4459-8A6A-EA85D9299DD1

P5875

Q33805259-B8D485AD-A5AB-4D49-AA52-6905BCC8956A

P698

Q33805259-F1EAE409-2F56-4492-9893-77C057E47404

P921

Q33805259-69923378-C171-48C6-9A8F-995E9019C153

P932

Q33805259-70996E98-9BA7-428E-A876-6D8BDDAA9A3E

P356

BMJ.316.7148.1858

P1433

P1476

Hormone replacement therapy an ...... dish Hip Fracture Study Group.

@en

P2093

B Y Farahmand

http://www.w3.org/2001/XMLSchema#string

I Persson

http://www.w3.org/2001/XMLSchema#string

J A Baron

http://www.w3.org/2001/XMLSchema#string

O Johnell

http://www.w3.org/2001/XMLSchema#string

P G Persson

http://www.w3.org/2001/XMLSchema#string

S Ljunghall

http://www.w3.org/2001/XMLSchema#string

P2860

Involutional osteoporosis.

Hormone therapy to prevent disease and prolong life in postmenopausal women.

Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

Calcium in the prevention and treatment of osteoporosis.

Role of oestrogen in the development of osteoporosis.

Estrogens, bone loss and preservation.

Progesterone as a bone-trophic hormone.

Heterogeneity of age-related fractures: implications for epidemiology.

Fracture protection provided by long-term estrogen treatment.

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

P304

1858-1863

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.316.7148.1858

http://www.w3.org/2001/XMLSchema#string

P407

P433

7148

http://www.w3.org/2001/XMLSchema#string

P478

316

http://www.w3.org/2001/XMLSchema#string

P50

Cecilia Magnusson

Karl Michaëlsson

P577

1998-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232268198

http://www.w3.org/2001/XMLSchema#string

P698

9632404

http://www.w3.org/2001/XMLSchema#string

P921

P932

28583

http://www.w3.org/2001/XMLSchema#string